Skip to content

Clinical trials

Phase 1/2 Hematologic Neoplasms trials in China

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Hematologic Neoplasms Phase: Phase 1/2 Country / region: China Clear all

22 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20131
20141
20162
20172
20191
20213
20221
20233
20243
20252
20263

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Recruiting9
Unknown status9
Completed2
Active, not recruiting1
Terminated1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Chinese PLA General Hospital6
Sichuan Baili Pharmaceutical Co., Ltd.2
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology2
AstraZeneca1
BeOne Medicines1
Beijing Biotech1
Grit Biotechnology1
Ruijin Hospital1
Sellas Life Sciences Group1
Shanghai EpimAb Biotherapeutics Co., Ltd.1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Hematologic Neoplasms22
Leukemia, Lymphocytic, Chronic, B-Cell7
Lymphoma, Mantle-Cell6
Recurrence5
Lymphoma, Follicular4
Lymphoma, Large B-Cell, Diffuse4
Leukemia, Myeloid, Acute3
Leukemia, Prolymphocytic3
Multiple Myeloma3
Lymphoma2

Trials

Showing 1 to 22 of 22. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.